Journal of International Psychiatry

[Abstract] Objective: To analyze effects of repeated transcranial magnetic stimulation (rTMS) combined with paroxetine on cognitive status, depression symptoms, serum 5-hydroxytryptamine (5-HT) and interleukin-1β (IL-1β) in patients with Parkinsons disease and depression (PD-D). Methods: 102 patients with PD-D treated in the hospital were enrolled and randomly divided into control group (paroxetine) and study group (rTMS+paroxetine) between February 2019 and March 2022, 51 cases in each group. Clinical curative effect, scores of Hamilton Depression Scale (HAMD), Self-rating Depression Scale (SDS), Montreal Cognitive Assessment Scale (MoCA) and Mini-Mental State Examination (MMSE), levels of serum 5-HT and IL-1β, and adverse reactions were compared between the two groups. Results: The response rate of treatment was higher in study group than control group (P<0.05). HAMD and SDS scores, and IL-1β were lower in study group than control group (P<0.05), while MoCA and MMSE scores, and 5-HT were higher in study group (P<0.05). The incidence of adverse reactions was lower in study group than control group (P<0.05). Conclusion: The rTMS combined with paroxetine can improve curative effect, effectively improve depression symptoms and cognitive status, regulate levels of serum 5-HT and IL-1β, and reduce adverse reactions in PD-D patients.

Key words: Repetitive transcranial magnetic stimulation; Paroxetine; Parkinsons disease complicated with depression